The "European Patients' Academy on Therapeutic Innovation" (EUPATI) will provide scientifically reliable, objective, comprehensive information to patients on the research and development process of medicines. It will increase the capacity of patients and the lay public to be effective advocates and advisors, eg, in clinical trials, with regulatory authorities and in ethics committees. A consortium of 30 organisations, led by the European Patients' Forum, comprises a unique combination of pan-European patient organisations, academic and not-for-profit organisations expert in patient and public engagement and EFPIA member companies. It will feature excellent state-of-the-art, high quality, objective education to patients, facilitating engagement and involvement.
EUPATI will make a substantial and measurable difference to patients, providing the tools and the knowledge for their empowerment and meaningful involvement in pharmaceutical innovation, safety of medicines and access to treatments. It will inform the general as well as the more hard-to-reach patient community, raising public awareness of the development of new treatments. Find out more about the Patients' Academy below.
The development of pharmaceutical medicines is a highly regulated, costly, long and complex process that is largely unknown to the general public. The benefits and risks of medical treatments are difficult to understand for patients. In an era of growing demand and emphasis on both quality and sustainability of healthcare, it is critical to address this major gap in public perception and knowledge. Better-informed patients and carers have a key role to play in the implementation of patient-centred clinical research strategies and approval processes, access to treatments and treatment optimisation approaches.
The European Patients' Academy (EUPATI) was initiated by and is led by major patient umbrella organisations, is welcomed by the European Pharmaceutical Industry and run by a strong multi-stakeholder Consortium. It will address training issues and significantly improve the availability of both patient-friendly information for the public as well as for educated patient experts that have the capacity and capability to contribute to medical research & development.
The European Patients' Academy will develop educational modules in the following areas:
Leaership of our project includes pan-European groups in patient advocacy, academia, not-for-profit organisations and EFPIA member companies, bringing in key expertise in patient advocacy as well as the processes of research and development in medicines.
The European Patients' Academy will reach out to three audiences: "Expert patients", health advocates and advocacy leaders, and the general public. It will target specifically patient organizations, advocacy leaders and the public in countries speaking English, German, Spanish, Polish, French, Russian and Italian.
The European Patients' Academy was launched in February 2012 and will run for five years. The five year project plan constitutes three key phases. The project is organized into seven work packages that will ensure the professional and efficient delivery of the project results.
The European Patients' Academy is a highly collaborative project with partners from very different fields including patient groups, academic organisations and pharmaceutical organisations. Objectivity, transparency and independence are vital prerequisites to ensure that EUPATI achieves its goals and is accepted and valued by both the patient community and the wider public.
Our commitment to transparency and independence is reflected in all aspects of the project.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
The Network is for patients and patient organisations, caregivers, academia, pharmaceutical & biotech companies, journalists, and anyone else interested in information on medicines research & development in understandable language. Membership in the network is free! Being a member of the EUPATI Network provides the following benefits: